USP19

Across TCGA pan-cancer cohorts, USP19 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated USP19 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher USP19 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP19 expression acts as an unfavorable survival marker.

LUAD, ACC, and LUSC are the cancer types where USP19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.254	0.815	<.001	23	view →
ACC	OS	Median	All	0.159	0.623	.017	12	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.118	0.408	.044	6	view →
LIHC	DFS	Median	All	0.224	0.557	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP19–LUAD (DFS)

Open the LUAD breakdown →